Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PBRM1 inact mut VHL loss |
Therapy | Belzutifan + PRT1419 |
Indication/Tumor Type | clear cell renal cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PBRM1 inact mut VHL loss | clear cell renal cell carcinoma | sensitive | Belzutifan + PRT1419 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of PRT1419 and Welireg (belzutifan) inhibited tumor growth of a clear cell renal cell carcinoma cell line xenograft model harboring an inactivating PBRM1 mutation and with loss of VHL (PMID: 38371625). | 38371625 |
PubMed Id | Reference Title | Details |
---|---|---|
(38371625) | PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer. | Full reference... |